Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myomo (MYO) Research & Development (2017 - 2025)

Myomo filings provide 9 years of Research & Development readings, the most recent being $1.5 million for Q3 2025.

  • On a quarterly basis, Research & Development rose 22.32% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 million, a 68.17% increase, with the full-year FY2024 number at $4.8 million, up 81.0% from a year prior.
  • Research & Development hit $1.5 million in Q3 2025 for Myomo, down from $2.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.0 million in Q2 2025 to a low of $476991.0 in Q1 2023.
  • Median Research & Development over the past 5 years was $717256.0 (2023), compared with a mean of $934997.1.
  • Biggest five-year swings in Research & Development: tumbled 36.56% in 2022 and later surged 100.47% in 2024.
  • Myomo's Research & Development stood at $787628.0 in 2021, then plummeted by 36.56% to $499674.0 in 2022, then surged by 75.72% to $878007.0 in 2023, then surged by 77.64% to $1.6 million in 2024, then decreased by 2.05% to $1.5 million in 2025.
  • The last three reported values for Research & Development were $1.5 million (Q3 2025), $2.0 million (Q2 2025), and $1.8 million (Q1 2025) per Business Quant data.